Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial

CONCLUSIONS: This exploratory proof-of-clinical-concept study supports the development of spesolimab as a new therapeutic option in HS. ClinicalTrials.gov identifier: NCT04762277.PMID:38576350 | DOI:10.1093/bjd/ljae144

Source: The British Journal of Dermatology - April 5, 2024 Category: Dermatology Authors: Afsaneh Alavi Errol Prens Alexa B Kimball John W Frew James G Krueger Sutirtha Mukhopadhyay Heli Gao Usha Ranganathan Nathalie B Ivanoff Ana C Hernandez Daly Christos C Zouboulis Source Type: research